Janus porphyrin-stabilized phase-transition theranostics for multimodal imaging-guided synergistic cancer therapy
Source abstract
Abstract
Acoustic and optical droplet vaporization (ADV/ODV) enables localized energy conversion through nanoscale phase transitions, offering a mechanism to couple imaging enhancement with therapeutic activation. However, achieving controlled vaporization while integrating multimodal imaging and therapy remains challenging. Here, we developed low-boiling-point fluorocarbons ( FO1 - FO4 ) as phase-transition liquids and Janus porphyrin amphiphiles ( TP1 and TP2 ) as energy mediators, which co-assemble into core-shell nanodroplets ( TFNP ) that unify vaporization dynamics with multimodal theranostics. TFNP responds to optical or acoustic excitation by converting droplets into microbubbles, amplifying fluorescence, photoacoustic, and ultrasound signals, while simultaneously activating photodynamic and sonodynamic therapy. Structure-property optimization identified TP2 as an effective interfacial energy mediator, fluorophore, sonosensitizer, and photosensitizer, and FO1 as a newly developed phase-transition liquid with a single intense 19 F magnetic resonance imaging ( 19 F MRI) signal and controllable vaporization. Compared with the commonly used perfluorohexane, FO1 provides TFNP with unparalleled photoacoustic, ultrasound, and 19 F MRI performance. Upon ADV/ODV triggering, TFNP synchronizes multimodal imaging enhancement with reactive oxygen species generation and anti-vascular effects, enabling spatially confined and temporally guided therapy. In vivo 19 F MRI permitted quantitative tracking of FO1 retention and revealed a theranostic window of less than 10 hours for ADV/ODV nanodroplets. These findings demonstrate that rational molecular and interfacial engineering can significantly improve phase-transition theranostic performance while highlighting the importance of imaging-guided temporal optimization.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (45)
Show source-provided references
1. The future of early cancer detection10.1038/s41591-022-01746-x ↗
2. Medical imaging and nuclear medicine: a lancet oncology commission10.1016/S1470-2045(20)30751-8 ↗
3. Improving image‐guided surgical and immunological tumor treatment efficacy by photothermal and photodynamic therapies based on a multifunctional NIR AIEgen10.1002/adma.202101158 ↗
4. Recent development of contrast agents for magnetic resonance and multimodal imaging of glioblastoma10.1186/s12951-022-01479-6 ↗
5. Recent advances in near-infrared-II hollow nanoplatforms for photothermal-based cancer treatment10.1186/s40824-022-00308-z ↗
6. Biomedical photoacoustics beyond thermal expansion using triggered nanodroplet vaporization for contrast-enhanced imaging10.1038/ncomms1627 ↗
7. Acoustic droplet vaporization is initiated by superharmonic focusing10.1073/pnas.1312171111 ↗
8. Contrast-enhanced ultrasound with sub-micron sized contrast agents detects insulitis in mouse models of type1 diabetes10.1038/s41467-020-15957-8 ↗
9. Intensified and controllable vaporization of phase-changeable nanodroplets induced by simultaneous exposure of laser and ultrasound10.1016/j.ultsonch.2023.106312 ↗
10. Concurrent anti-vascular therapy and chemotherapy in solid tumors using drug-loaded acoustic nanodroplet vaporization10.1016/j.actbio.2016.11.018 ↗
11. Perfluorohexane emulsions induce macrophage-stimulating effects through iNOS expression10.1021/acsabm.5c00191 ↗
12. Ultrasound‐activated sonophage synergizes sonodynamic therapy and saltoptosis for solid tumor eradication
13. Body interventional MRI for diagnostic and interventional radiologists: current practice and future prospects10.1148/rg.2021210040 ↗
14. Studying osteoarthritis with artificial intelligence applied to magnetic resonance imaging10.1038/s41584-021-00719-7 ↗
15. Self-immolative fluorinated nanotheranostics amplifying 19F MRI signals for tumor-specific imaging and photodynamic therapy10.1016/j.jconrel.2025.114217 ↗
16. Tumor microenvironment activated photoacoustic-fluorescence bimodal nanoprobe for precise chemo-immunotherapy and immune response tracing of glioblastoma10.1021/acsnano.3c03378 ↗
17. Fluorescence, ultrasonic and photoacoustic imaging for analysis and diagnosis of diseases10.1039/D2CC06654H ↗
18. Hyperspectral fluorescence imaging with a new polarity‐ultrasensitive fluorescent probe
19. Ultrasound imaging of tumor vascular CD93 with MMRN2 modified microbubbles for immune microenvironment prediction
20. A versatile theranostic nanoemulsion for architecture-dependent multimodal imaging and dually augmented photodynamic therapy
21. Recent strategies to develop innovative photosensitizers for enhanced photodynamic therapy10.1021/acs.chemrev.1c00381 ↗
22. Selenium‐containing type‐I organic photosensitizers with dual reactive oxygen species of superoxide and hydroxyl radicals as switch‐hitter for photodynamic therapy
23. An ethacrynic acid‐brominated BODIPY photosensitizer (EA‐BPS) construct enhances the lethality of reactive oxygen species in hypoxic tumor‐targeted photodynamic therapy10.1002/anie.202012687 ↗
24. Newly developed strategies for improving sonodynamic therapy10.1039/D0MH00613K ↗
25. ROS-augmented and tumor-microenvironment responsive biodegradable nanoplatform for enhancing chemo-sonodynamic therapy10.1016/j.biomaterials.2020.119761 ↗
26. Emerging applications of photodynamic and sonodynamic therapies in orthopedic disorders: mechanisms, challenges, and future directions10.1002/adhm.202502565 ↗
27. Light/X-ray/ultrasound activated delayed photon emission of organic molecular probes for optical imaging: mechanisms, design strategies, and biomedical applications10.1039/D4CS00599F ↗
28. Endogenous near‐infrared chemiluminescence: imaging‐guided non‐invasive thrombolysis and anti‐inflammation based on a heteronuclear transition metal complex10.4028/b-XDTcg5 ↗
29. Lanthanide porphyrinoids as molecular theranostics10.1039/D2CS00275B ↗
30. Challenges of aufheben to promote druglikeness: chemical modification strategies to improve aqueous solubility and permeability10.1021/acs.jmedchem.5c00287 ↗
31. Characterising the chemical and physical properties of phase-change nanodroplets10.1016/j.ultsonch.2023.106445 ↗
32. A nanoarchitectonic approach enables triple modal synergistic therapies to enhance antitumor effects
33. Erythrocyte membrane‐coated invisible acoustic‐sensitive nanoparticle for inducing tumor thrombotic infarction by precisely damaging tumor vascular endothelium10.1002/smll.202201933 ↗
34. An imaging-guided self-amplifying photo-immunotherapeutic nanoparticle for STING pathway activation and enhanced cancer therapy10.1186/s12951-025-03536-2 ↗
35. Fluorinated cryptophane-A and porphyrin-based theranostics for multimodal imaging-guided photodynamic therapy10.1039/D0CC00694G ↗
36. Conditional singlet oxygen generation through a bioorthogonal DNA‐targeted tetrazine reaction10.1002/anie.201907093 ↗
37. Fluorinated macromolecular amphiphiles as prototypic molecular drones10.1073/pnas.2405877121 ↗
38. Phase change materials for life science applications10.1002/adfm.202213455 ↗
39. Fluorocarbon nanodroplets: their formation and stability in complex solution systems10.1021/acs.langmuir.4c00475 ↗
40. Nanoprecipitation and the “ouzo effect”: application to drug delivery devices10.1016/j.addr.2013.12.009 ↗
41. Ouzo effect examined at the nanoscale via direct observation of droplet nucleation and morphology10.1021/acscentsci.2c01194 ↗
42. Spontaneous nucleation of stable perfluorocarbon emulsions for ultrasound contrast agents10.1021/acs.nanolett.8b03585 ↗
43. Porphyrin-based fluorescent probes for imaging mitochondria in living cells10.1016/j.dyepig.2024.112369 ↗
44. 19F MRI/CEUS dual imaging‐guided sonodynamic therapy enhances immune checkpoint blockade in triple‐negative breast cancer
45. Monotherapy and combination therapy using anti‐angiogenic nanoagents to fight cancer10.1002/adma.202005155 ↗